Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS5352446 A
Publication typeGrant
Application numberUS 07/983,273
Publication dateOct 4, 1994
Filing dateNov 30, 1992
Priority dateMar 25, 1986
Fee statusPaid
Publication number07983273, 983273, US 5352446 A, US 5352446A, US-A-5352446, US5352446 A, US5352446A
InventorsThomas Lehner
Original AssigneeCouncil Of Governors Of The United Medical And Dental Schools Of Guy's And St. Thomas's Hospitals
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Applying antibodies to tooth surfaces
US 5352446 A
A method of combatting dental caries in a mammal comprises topical application to a surface of a tooth in the mammals mouth of a monoclonal antibody raised against antigen I or antigen I/II of Streptococcus mutans serotype c.
Previous page
Next page
I claim:
1. A method of combatting dental caries in a mammal, which comprises topically applying to a surface of a tooth in the mouth of said mammal the monoclonal antibody produced by the hybridoma deposited in the European Collection of Animal Cell Cultures Under the Deposit No. 86031901.
2. The method according to claim 1, wherein the monoclonal antibody is painted onto the surface of the tooth.
3. The method according to claim 1, wherein the monoclonal antibody is applied to the surface of the tooth from a tooth paste, mouthwash, chewing gum, lozenge or gel.
4. The method according to claim 1, wherein about 10-100micrograms of antibody are applied per tooth on each application.

This application is a continuation of application Ser. No. 07/841,783, filed on Mar. 2, 1992, now abandoned which is continuation of Ser. No. 07/616,829, filed on Nov. 20, 1990, abandoned, which is a continuation of Ser. No. 07/120,690 filed Nov. 9, 1987, abandoned, which is a continuation of Ser. No. 06/843,690, filed Mar. 25, 1986, abandoned.


This invention relates to vaccines against dental caries.


Streptococcus mutans has been recognised for many years as the major organism responsible for the development of dental caries in mammals. Various vaccines have been proposed in the past based on various antigenic fragments of S. mutans. One such vaccine is described in British Patent No. 2,060,647 based upon the antigen known as I or I/II. Antigen I has a molecular weight, as determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) of 146-155 Kd. Antigen I/II is believed to be a conjugate of antigen I and antigen II, this I, II antigen having a molecular weight determined by SDS-PAGE of 175-195 Kd. U.S. patent application Ser. No. 579,117 now U.S. Pat. No. 4,594,244 describes antigen X which is a much smaller molecule having a molecular weight, determined by SDS-PAGE of about 3.5-4.5 Kd but which appears to include the same antigenic determinants included within antigens I and I/II.

Antibodies against antigens I, I/II and X are known. The above-mentioned British Patent describes the raising of antibodies against antigens I and I/II by conventional procedures in experimental animals, for example rhesus monkeys, rabbits and mice. These antibodies are proposed primarily for the purification of the antigen by affinity chromatography but the Patent Specification mentions the possibility of using such antibodies for passive immunisation by conventional means. Conventional passive immunisation involves parenteral administration of the antibodies but while such techniques are theoretically available, as a practical matter, passive immunisation has never been regarded as clinically attractive and indeed, the British Patent refers to the preferred use of the antigenic materials for direct immunisation.

Monoclonal antibodies against antigen I and antigen I/II are described in Smith et al, Infection and Immunity, Volume 46, No. 1, pages 168-175 (1984). This Paper describes the specificities of the various monoclonal antibodies by direct binding and inhibition with the pure streptococcal antigens with a solid phase radioassay. Conventional antisera to S. mutans serotype c, of the type described in the above-mentioned British Patent, cross-react with serotypes c, e and f (and g) while the monoclonal antibodies derived from antigen I/II of serotype c react predominantly with serotype c antigen and shows low titre reactivity with serotype f and possibly e. The slight cross-reactivity between S. mutans cells of serotype c and f could be further differentiated by absorption of any of the three monoclonal antibodies to I/II with cells of serotype c. Parallel studies of monoclonal antibodies with cells of S. mutans and their ammonium sulphate precipitated culture supernatants suggested that some antigenic determinants are retained predominantly on the cell surface but others are readily shed into culture medium so that they are detected both on the cell surface and in the culture medium. Unlike the polyclonal antibodies, the monoclonal antibodies are capable of discriminating single antigenic determinants and the Paper suggests that this can be applied to the study of the shedding of antigens from microorganisms into the environment such as the gut or gingival sulcus.


It has now been surprisingly found that the monoclonal antibodies against S. mutans antigens I and I/II can be effectively used topically in passive immunisation to provide inhibition of the development of S. mutans on the teeth of mammals for extended periods of time.

Accordingly, the present invention provides a method of combatting dental caries in a mammal which comprises topical application to a surface of a tooth in the mammal's mouth of a monoclonal antibody raised against antigen I or antigen I/II of Streptococcus mutans serotype c.


While the present invention is directed primarily to humans, the problem of dental caries is not confined to humans but arises in other mammals including non-human primates, domestic and farm animals and particularly in those cases where the non-human mammal eats a substantial proportion of food including sugars.

The monoclonal antibodies used in this invention may be applied to the tooth in the mouth of the mammal by any convenient method. Numerous methods are now available for the treatment of teeth with various materials for various purposes. If the treatment is to be carried out by a Dental Surgeon, then the monoclonal antibody is conveniently applied by painting the surface of the tooth. If the monoclonal antibodies are to be self-applied, then the monoclonal antibodies may be included in a toothpaste, mouthwash, chewing gum, lozenge or gel. As will be described in more detail below, the duration of protection afforded by the method of the present invention is surprisingly long but the frequency of the topical application is primarily one for the users personal convenience. Methods of self-application from toothpastes etc., can result in applications being repeated perhaps daily while the use of lozenges can result in more frequent application of the antibody. Chewing gums and gels may be regarded, for this purpose, as providing a certain amount of sustained release of the antibody over a period of half-an-hour or more and indeed, if sustained release of the antibody is required, then appropriate formulations can be used that will result in slow release of antibody into the mouth from the formulation as a result of the temperature or saliva conditions etc., found in the mouth. In certain instances, it may be desirable to provide a more formal prolonged contact of the antibody with the tooth surface and in such cases, appropriate tooth masks can be used that will cover the tooth after it has been coated with antibody and prevent the antibody from being removed, e.g. by saliva, for a predetermined period.

It is important that the antibody be brought into contact with the surface of the tooth and ideally should be applied to all of the smooth and occlusal surfaces of the tooth. It is not detrimental for the antibody to contact the gum but the protection afforded by the present invention does appear to result primarily if not exclusively from the contact of the antibody with the surface of the tooth itself.

The exact amount of antibody that is applied does not appear to be critical since, in a method of this type, repeated self-application of antibody is not difficult and indeed, particularly after initial treatment by a Dental Surgeon, maintenance or top-up treatment can be carried out by the user at whatever frequency is desirable. By way of guidance, it can be indicated that somewhere of the order of 10 to 100 micrograms of antibody can be applied to each tooth on each occasion that antibody is applied but amounts of antibody outside this range can certainly be applied without causing detriment to the subject. The use of insufficient quantities of antibody simply means that the level of protection is not as great as would otherwise be obtainable while the use of excessive amounts of antibody does not improve the protection and simply results in unnecessary use of antibody.

The exact formulation for the antibody is not a matter of critical importance but depends entirely upon the method of application to be adopted and the convenience of the user. In all cases, it is important to formulate the antibody in an environment of appropriate pH and which is free from other deleterious materials which might bring about protein degradation and the formulation should, of course, also be free from microbial impurity that would be deleterious in the subject's mouth. For example, for use in the dental surgery, the antibody could be formulated as a simple aqueous dispersion containing somewhere in the region of 0.1 to 10 milligrams of antibody per 100 microlitres of liquid and a liquid of such concentration could be applied to the tooth at the rate of about 1 to 10 microlitres of dispersion per tooth. Where the antibody is to be formulated for self-administration, then the concentration can be selected bearing in mind the above guidelines, the quantities of the formulation that are normally taken on each occasion of self-administration and the fact that over administration of antibody will not be deleterious.

The monoclonal antibody to be used in this invention can be raised by conventional hybridoma technology. Thus, mice may be injected with the selected antigen I or antigen I/II as immunogen and spleen cells from the immunised mice subsequently fused with mouse myeloma cells by the techniques originally pioneered by Kohler & Milstein and the later developments thereof. Detailed procedures for the production of monoclonal antibodies that can be used in the present invention are set out in Smith et al Infection and Immunity, Volume 46, No. 1, pages 168-175 (1984), the disclosure of which is incorporated in this specification by this reference. Smith et al describes in Table 1 the production of four specific monoclonal antibodies, any of which are suitable for use in the present invention. Table 1 describes one IgG 1 antibody and two IgG 2a antibodies against antigen I/II that are coded 2B1, 2D4, and B4. A further IgG 1 antibody against antigen I is described and coded 6A6. Repetition of the detailed procedures described in Smith et al will result in the production of further monoclonal antibodies against antigen I and antigen I/II which, while, almost by definition, cannot be identical to the monoclonal antibodies described in Table 1, will be very similar to those antibodies and will behave immunogenically in an identical fashion.

One representative hybridoma produced by the techniques described in the Smith et al Paper, prepared from a mouse that has been immunised by antigen I/II has been deposited under the conditions of the Budapest Treaty with the European Collection of Animal Cell Cultures (ECACC) at the Public Health Laboratory Service Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SP4OJG, England. The ECACC has been designated an International Depository Authority under the Budapest Treaty 1977. The deposit made in connection with this Patent Application was made on 19th Mar. 1986 and, has been given the Deposit Number 86031901.


This Example describes the use of monoclonal antibodies to protect the teeth of rhesus monkeys. The test animals were 9 young rhesus monkeys having all their deciduous teeth but where none of their permanent teeth had erupted. The monkeys were fed on a human-type diet of sandwiches, eggs, bananas, oranges and about 15% sugar. It is well recognised that under these conditions, unprotected monkeys develop indigenous S. mutans serotype c in their dental plaque and that this leads to the development of dental caries.

The monkeys were protected with monoclonal antibody that was prepared by the procedure described by Smith et al, Infection and Immunity, Volume 46, No. 1, pages 168-175 (1984) where the immunogen used for the mice was antigen I/II of S. mutans serotype c. The material used for passive immunisation was whole ascites fluid. On each occasion that immunisation took place, the teeth of the monkeys was dried with gauze and about 100 microlitres (containing 1 mg of IgG) of monoclonal antibody was applied to the smooth and occlusal surfaces of all of the teeth (about 5 microlitres of monoclonal antibody per tooth). To avoid dilution and washing away of the monoclonal antibody by saliva, silicon rubber appliances, moulded to fit the teeth and gums of the individual monkeys, were fitted to their teeth and maintained with slight digital pressure for 5 minutes.

The group of 9 monkeys was divided into 5 control monkeys and 4 test monkeys. The test monkeys were immunised on 12 occasions throughout the test, at weekly intervals for the first 5 weeks with immunisation No. 6 at 7 weeks, No. 7 at 12 weeks, No. 8 at 18 weeks, No. 9 at 22 weeks, No. 10 at 25 weeks, No. 11 at 30 weeks and No. 12 at 38 weeks. On each occasion that the test monkeys were immunised, the 5 control monkeys had saline applied to their teeth.

The teeth were examined at about 2 monthly intervals with a probe and mirror as well as by X-rays. The mean ( the standard error) number of carious lesions per animal is regarded as the caries score.

To determine the extent of development of S. mutans, dental plaque was collected separately from the smooth surfaces of the upper central incisors and from the fissures of the upper left second molar with sterile probes and placed into transport medium. The proportion of S. mutans grown on tryptone yeast extract - L-cystine medium was determined and expressed as a mean ( the standard error) percentage of the total number of colonies grown on that medium.

The tests were carried out over a period of about one year and the results are shown in Tables 1, 2 and 3.

              TABLE 1______________________________________Caries ScoreTime - Weeks 0     8      16  20   28  32   36  48______________________________________Immunised monkeys        0     0      0   0    0   0    0   0Control monkeys        0     0      0   0    1   1.8  3.0 3.0______________________________________

              TABLE 2______________________________________% S. mutans in fissuresTime - Weeks   0     12      20  28    36  48______________________________________Immunised monkeys          0      0       2   3     0   2Control monkeys          0     30      27  21    21  20______________________________________

              TABLE 3______________________________________% S. mutans on smooth surfacesTime - Weeks   0     12      20  28    36  48______________________________________Immunised monkeys          0      0       4   8     0   2Control monkeys          0     30      31  42    32  31______________________________________

The results show that the application of the monoclonal antibody to the deciduous teeth of the rhesus monkeys prevented the development of caries over a period of one year as compared with a mean ( the standard error) of 3.0 .sup. 2.0 carious lesions per control animal. There were 8 smooth surface and 7 fissure carious lesions in the control animals so that both smooth surface and fissure caries were prevented in the immunised animals. Caries was found in 3 of the control monkeys but in none of the passively immunised monkeys.


Colonisation of both smooth surfaces and fissures of teeth by S. mutans was significantly lower in those animals whose teeth were treated with the monoclonal antibody than in the untreated animals. The proportion of S. mutans in the fissures of teeth of control monkeys was between 21 and 31% as compared with 0-2% in immunised monkeys. The results for smooth surface plaque was similar, 30-44% in control monkeys and 0-8% in immunised monkeys.


Eight human patients had monoclonal antibodies (McAb; 2D4) or saline applied on three occasions (day 1, 2 and 5). The McAb 2D4 (an IgG2a material) was prepared to streptococcal antigen (SA) I/II according to Smith et al 1984 mentioned in Example 1. The mouse ascites fluid was purified by ammonium sulphate precipitation, followed by DEAE cellulose chromatography. The recovered protein was freeze-dried and reconstituted in PBS to a concentration of 10 mg/ml. This was centrifuged at 120,000 g for 30 minutes and passed through a 0.22 μm filter. The final preparation, stored at -20 C., showed 6.8% binding to SA I/II and a titre of 10-6 in radioimmunoassay. Samples of 5 μl of McAb (or saline) were applied to the dried buccal and occlusal surfaces of each tooth on day 1, 2 and 5. Dilution or washing away by saliva was prevented, using custom made, silicone impression trays. The patients were asked to avoid eating, drinking and rinsing for the next 30 minutes. Implantation of Strep mutans was attempted on day 8, using 108 -109 per ml of a live, wild strain of streptomycin resistant Strep. mutans (K2). This was cultured in Todd Hewitt broth containing 1 mg/ml streptomycin, for 18 hours at 37 C. The resultant growth was centrifuged and washed twice in sterile phosphate buffered saline (PBS), and resuspended in PBS. The patients were asked to rinse with 10 ml of the Strep. mutans preparation, one hour after toothbrushing, and 2 minutes after rinsing with 10% sucrose.

Dental plaque samples were collected, from the smooth surfaces of the first incisors and first molars, and the fissures of the molars and pre-molars into a transport medium, (Bowden G. H. and Hardie J. M., 1971 "Anaerobic organisms from the human mouth" page 177 of Isolation of Anaerobes, SAB Technical Series No. 5, Soc. of Applied Bacteriology, London) at the intervals indicated. Unstimulated saliva was collected in cooled sterile tubes over a period of 4 minutes. The bacterial samples were plated, within one hour of collection, onto TYC agar (Lab M) with streptomycin (1 mg/ml), and blood agar in serial dilutions. In addition, saliva was plated onto TYC containing sucrose and bacitracin supplement. The TYC based plates were incubated for 72 hours at 37 C. under anaerobic conditions (Gaspak) and the blood based plated for 120 hours. The proportion of Strep. mutans was expressed as a percentage of the total colony count on the TYC medium. Serum, crevicular fluid and saliva were collected, before, during and after the experimental period, as described by Lehner et al Infection Immunity, Vol. 50, No. 3 pages 796-799 (1985). The samples were assayed for anti-SA I/II antibodies, by a solid phase radioimmunoassay (Smith and Lehner (1981), Clin, Exp. Immunol, 42, pages 417-424).

The results are set out in Table 4 and 5 below.

                                  TABLE 4__________________________________________________________________________% S. mutans in fissuresTime-Days 0 1  3/5             8/12                20/22                    34/36                        63/78                            100/120__________________________________________________________________________Immunised subjects     0.0       0.6          0.02             0  0.003                    0   0   0.009Control subjects     0.0       0.11          0.36             0.12                0.66                    0.23                        0.23                            0.56__________________________________________________________________________

                                  TABLE 5__________________________________________________________________________% S. mutans on smooth surfacesTime-Days 0 1  3/5             8/12                20/22                    34/36                        63/78                            100/120__________________________________________________________________________Immunised subjects     0.0       0.25          0.13             0.13                0.22                    0.3 0.003                            0.004Control subjects     0.0       0.91          1.91             1.6                0.9 1.5 0.77                            0.001__________________________________________________________________________
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4133875 *Feb 23, 1978Jan 9, 1979Forsyth Dental Infirmary For ChildrenMethod of controlling dental caries with streptococcus mutans mutant strains
US4150116 *Feb 21, 1978Apr 17, 1979Forsyth Dental Infirmary For ChildrenImmunization against dental caries with glucosyltransferase antigens
US4324782 *Mar 10, 1977Apr 13, 1982Beck Lee RDental caries inhibiting product of immunized cow's milk having antibodies specific to killed Streptococcus mutans cells
US4521513 *Jun 4, 1982Jun 4, 1985The Secretary Of State Of Social Services In Her Britannic Majesty's Government Of The United Kingdon Of Great Brtian And Northern IrelandProtection against dental caries
US4594244 *Feb 10, 1984Jun 10, 1986Council Of Governors Of The United Medical And Dental Schools Of Guy's And St. Thomas's HospitalsAntigenic materials
US4659561 *Mar 22, 1985Apr 21, 1987The University Of Vermont And State Agricultural CollegeAntigen from streptococcus
US4693888 *Aug 7, 1984Sep 15, 1987Lion CorporationAntibody obtained by immunizing mammal with streptococcus mutans derived antigen, and synergist
US4741999 *Feb 26, 1986May 3, 1988The Research Foundation Of State University Of New YorkMonoclonal antibodies useful in the identification of microorganisms causing periodontal disease
US5240704 *Jun 22, 1992Aug 31, 1993Kitasato KenkyushoVaccine, antibodies & antibody-containing compositions for inhibiting human dental caries induced by streptococcus mutans
GB2060647A * Title not available
JPS6038327A * Title not available
Non-Patent Citations
1 *Diamond et al JAMA 248, 1982, pp. 3165 3169.
2Diamond et al JAMA 248, 1982, pp. 3165-3169.
3 *Lehner et al. (1981) Infect. Immun. 34, 407 415.
4Lehner et al. (1981) Infect. Immun. 34, 407-415.
5 *Lehner et al. (1985) Infect. Immun. 50, 796 799.
6Lehner et al. (1985) Infect. Immun. 50, 796-799.
7 *Sevier et al, Clin. Chem 27(11) 1981, pp. 1797 1806.
8Sevier et al, Clin. Chem 27(11) 1981, pp. 1797-1806.
9 *Smith et al, Inf and Immunity 46, 1984, pp. 168 175.
10Smith et al, Inf and Immunity 46, 1984, pp. 168-175.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6046037 *May 4, 1995Apr 4, 2000Hiatt; Andrew C.Method for producing immunoglobulins containing protection proteins in plants and their use
US6231857Aug 20, 1999May 15, 2001The Regents Of The University Of CaliforniaAntibodies to S. mutans and uses thereof
US6303341May 14, 1999Oct 16, 2001Planet Biotechnology, Inc.Genetically engineered antibody for use in immunotherapy
US6808709Nov 20, 2000Oct 26, 2004The Regents Of The University Of CaliforniaImmunoglobulins containing protection proteins and their use
US7211389Feb 18, 2004May 1, 2007The Regents Of The University Of CaliforniaMethod for producing immunoglobulins containing protection proteins and their use
US7846895Sep 6, 2007Dec 7, 2010The Regents Of The University Of CaliforniaSelectively/specifically targeted antimicrobial peptide (STAMP) which comprises a targeting peptide and an antimicrobial peptide; "targeted" antibiotic therapies to combat mucosal pathogens with a minimal impact on normal microflora; e.g. peptide G10KHc and a protease inhibitor and/or rhDNase
US7875598Mar 4, 2004Jan 25, 2011The Regents Of The University Of Californiayeast or fungal acitvity inhibiting using a composition comprising polyphyllin D ; for oral microbial infections, including periodontal disease and dental caries; (3 beta ,25R)-spirost-5-en-3-yl O- alpha -L-arabinofuranosyl-(1 --> 4)-O-[6-deoxy- alpha -L-mannopyranosyl-(1 --> 2)]- beta -D-glucopyranoside
US7951378Apr 28, 2001May 31, 2011Planet Biotechnology Inc.Modified cell adhesion molecule comprising immunoglobulin heavy chain fusion for treatment and prevention of respiratory system disorders
US8182818Apr 2, 2010May 22, 2012Avaxia Biologics, Inc.Methods of using anti-TNF antibodies for treating radiation damage to the digestive tract
US8680058Nov 2, 2010Mar 25, 2014The Regents Of The University Of CaliforniaSelectively targeted antimicrobial peptides and the use thereof
EP2725035A1Oct 2, 2008Apr 30, 2014Avaxia Biologics, Inc.Antibody therapy for use in the digestive tract
WO2002015931A1 *Aug 24, 2000Feb 28, 2002Maxwell H AndersonImmunologic method for the prevention of dental caries
U.S. Classification424/150.1, 424/49, 530/388.4
International ClassificationC07K16/12, A61K39/395, A61K6/00, A61K38/00, A61Q11/00, A61K8/64
Cooperative ClassificationA61Q11/00, C07K16/1275, A61K8/64, A61K38/00
European ClassificationA61K8/64, A61K6/00, C07K16/12B12, A61Q11/00
Legal Events
Oct 3, 2006FPAYFee payment
Year of fee payment: 12
Oct 3, 2006SULPSurcharge for late payment
Year of fee payment: 11
Apr 19, 2006REMIMaintenance fee reminder mailed
Aug 1, 2002SULPSurcharge for late payment
Year of fee payment: 7
Aug 1, 2002FPAYFee payment
Year of fee payment: 8
Apr 23, 2002REMIMaintenance fee reminder mailed
Jun 8, 1998SULPSurcharge for late payment
Jun 8, 1998FPAYFee payment
Year of fee payment: 4
Nov 30, 1992ASAssignment
Effective date: 19860319